A Phase 3 interventional study of Rocuronium bromide (Zemuron) and Rocuronium bromide (Zemuron) in Anesthesia, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged Up to 17 Years. Per ClinicalTrials.gov, last updated 2015-06-01.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The primary purpose of this study is to evaluate the time course of muscle relaxation after administration of three different single intravenous bolus doses of rocuronium bromide for intubation (insertion of a tube through the nose or mouth into the trachea to provide artificial ventilation) in term neonates (birth to \<28 days old), infants (28 days to \<=3 months) and toddlers (>3 months to \<=2 years), children (2 years to less than or equal to 11 years of age), and adolescents (>11 years to less than or equal to 17 years of age).
Subjects in each of the age groups will be randomized to one of 3 Zemuron® doses: 0.45 mg/kg, 0.6 mg/kg, or 1.0 mg/kg.
Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
0.45 mg/kg Zemuron
Drug: Rocuronium bromide (Zemuron)
0.6 mg/kg Zemuron
Drug: Rocuronium bromide (Zemuron)
1.0 mg/kg Zemuron
Drug: Rocuronium bromide (Zemuron)
A single IV Zemuron bolus dose of 0.45 mg/kg prior to intubation.
Also known as: ORG 9426, SCH 900085, Zemuron
A single IV Zemuron bolus dose of 0.6 mg/kg prior to intubation.
Also known as: ORG 9426, SCH 900085, Zemuron
A single IV Zemuron bolus dose of 1.0 mg/kg prior to intubation.
Also known as: ORG 9426, SCH 900085, Zemuron
Time to reappearance of T3 (time from end-administration of Zemuron to reappearance of the third twitch of a TOF stimulation)
Time frame: during surgery
Onset time, maximum block, time to reappearance of T1, Recovery to TOF 0.7, 0.8 and 0.9 and intubation score
Time frame: during and after surgery
No study locations are listed for this record.
The record gives a start of Dec 2004, a primary completion of Jul 2007 and a completion of Jul 2007. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Rocuronium